Pneumotox » Drug » Status post-lung transplantation

Status post-lung transplantation

There are many reviews on pathology and infection specific to this context (PMID 17683184). See also adverse respiratory complications of each specific drug used in LT recipients

Last update : 20/09/2015

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

I.x Pleuroparenchymal fibroelastosis (PPFE)

XIII.b Lymphoproliferative disease (pulmonary, endobronchial, endothoracic)

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

XV.ap Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)

XV.bp Path: Post-transplant lymphoproliferative disease (PTLD)

XVII.l Scedosporium pulmonary infection

XIX.g BAL: Atypical epithelial cells (at times poetically named

Diagnosing DIRD

Drug and radiation history

Drug singularity - Correct identification of the drug

Consistent timing of exposure v. onset of symptoms

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

Careful exlusion of another cause

Remission of symptoms with removal of drug

Recurrence with rechallenge (rarely advisable)

Causality assessment

More detailed checklist

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France